GTS Securities’s Silexion Therapeutics Warrant SLXNW Stock Holding History

GTS Securities’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,498	Closed	-$799	–	1647
2024 Q4	$799	Buy	+23,498	New	+$945	﹤0.01%	1209

Other funds holding SLXNW

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

GTS Securities's SLXNW Position: Q1 2025 in Review

GTS Securities sold out of Silexion Therapeutics Warrant (SLXNW) in Q1 2025, closing a stake of 23,498 shares — an estimated $799 sold.

GTS Securities first reported a position in SLXNW in Q4 2024 and held it in 1 quarter. The position peaked at $799 in Q4 2024. 25 funds tracked by Wall St. Rank hold SLXNW as of Q1 2025.

GTS Securities reported no remaining Silexion Therapeutics Warrant position as of Q1 2025 after selling out during the quarter.
GTS Securities sold 23,498 Silexion Therapeutics Warrant shares in Q1 2025, an estimated $799.
GTS Securities first reported a position in Silexion Therapeutics Warrant in Q4 2024 and held it in 1 quarter.
GTS Securities's Silexion Therapeutics Warrant position peaked at $799 in Q4 2024.
25 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2025.

Based on GTS Securities's 13F filing for Q1 2025, filed 15 May 2025.